Document Detail


Adverse and beneficial effects of tocolytic therapy.
MedLine Citation:
PMID:  11707019     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In addition to questions raised about the efficacy of many tocolytics, appropriate concern has been voiced about the safety of these potent drugs. Although some degree of risk for adverse effects with drugs promising a strong therapeutic effect can be accepted, caution needs to be exercised when benefits are marginal or unproven. Unfortunately, some of the tocolytics, most notably the betamimetics and magnesium sulfate, have been found to have considerable potential for adverse maternal cardiovascular and respiratory effects. Although less clearly established, the use of indomethacin appears to be associated with increased fetal and neonatal risks. Concerning magnesium sulfate, in addition to the well-known maternal effects, the accumulating evidence showing an increased frequency of adverse outcomes in the fetus and neonate has led to the recommendations to abandon its use entirely as a tocolytic. Given the limitations of our current state of knowledge, nifedipine would appear to be among the more efficacious and safer tocolytics available to use when properly indicated.
Authors:
P G Pryde; R E Besinger; J G Gianopoulos; R Mittendorf
Related Documents :
1860779 - Drug induced suicidal ideation.
3688779 - Cytostatic extravasations.
16640819 - Fatal interstitial pneumonitis related to rituximab-containing regimen.
15452739 - Approval times and the safety of new pharmaceuticals.
149499 - Adverse reactions to co-trimoxazole in hospitalized medical patients.
9785339 - Adverse effects of neuromuscular blockers and their antagonists.
14705869 - Clinical relevance of p-glycoprotein in drug therapy.
6613989 - Antimicrobial therapy in patients with impaired renal function.
3237559 - Pharmacokinetics of carbamazepine in psychiatric patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in perinatology     Volume:  25     ISSN:  0146-0005     ISO Abbreviation:  Semin. Perinatol.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-11-14     Completed Date:  2002-02-28     Revised Date:  2008-09-03    
Medline Journal Info:
Nlm Unique ID:  7801132     Medline TA:  Semin Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  316-40     Citation Subset:  IM    
Affiliation:
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Wisconsin, Madison, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / adverse effects,  therapeutic use
Calcium Channel Blockers / adverse effects,  therapeutic use
Cyclooxygenase Inhibitors / adverse effects,  therapeutic use
Female
Fetal Death / chemically induced
Fetal Diseases / chemically induced
Humans
Magnesium Sulfate / adverse effects,  therapeutic use
Obstetric Labor, Premature / drug therapy*
Oxytocin / antagonists & inhibitors
Pregnancy
Randomized Controlled Trials as Topic
Tocolytic Agents / adverse effects*,  therapeutic use*
Vasotocin / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Calcium Channel Blockers; 0/Cyclooxygenase Inhibitors; 0/Tocolytic Agents; 50-56-6/Oxytocin; 7487-88-9/Magnesium Sulfate; 9034-50-8/Vasotocin; 90779-69-4/atosiban

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Infection, antibiotics, and preterm delivery.
Next Document:  Antenatal corticosteroids for preterm birth.